Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 20/20 | 1.00 |
| ▸ | KCNJ11 | Q14654 | 20/20 | 1.00 |
| ▸ | ABCC8 | Q09428 | 19/20 | 1.00 |
| ▸ | KCNJ8 | Q15842 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7855041 | 1.00 | ABCC9 (1.00) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL4255051 | 1.00 | ABCC9 (1.00) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7098226 | 0.93 | ABCC9 (1.00) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7851613 | 0.93 | ABCC9 (1.00) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7096160 | 0.93 | ABCC9 (1.00) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7843452 | 0.91 | ABCC9 (1.00) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7097711 | 0.90 | ABCC9 (0.82) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7823829 | 0.90 | ABCC9 (0.84) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL7856207 | 0.90 | ABCC9 (1.00) | ABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL4261083 | 0.89 | ABCC9 (1.00) | ABCC9KCNJ11ABCC8KCNJ8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | PYGB, PC, KCNN3 | ABCC9 384/4885KCNJ11 18/4885ABCC8 415/4885 |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | PC, LIPE, ATP5ME | ABCC9 482/4885KCNJ11 24/4885ABCC8 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.